FibroGen And AstraZeneca Agree To Terminate Roxadustat Collaboration Agreement Entered On Jul. 30, 2013; FibroGen Regains All Rights To Roxadusta In United States And Other AstraZeneca Territories, Except China And South Korea
Portfolio Pulse from Benzinga Newsdesk
FibroGen and AstraZeneca have mutually agreed to terminate their collaboration agreement on Roxadustat, which was initially entered into on July 30, 2013. As a result, FibroGen regains all rights to Roxadustat in the United States and other AstraZeneca territories, with the exception of China and South Korea.
February 26, 2024 | 9:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
FibroGen regains full rights to Roxadustat in the US and other territories, excluding China and South Korea, after terminating the collaboration with AstraZeneca.
Regaining full rights to Roxadustat in key markets could potentially allow FibroGen to have more control over the drug's development and commercialization strategy, which might be viewed positively by investors.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
NEGATIVE IMPACT
AstraZeneca and FibroGen have ended their collaboration on Roxadustat, with AstraZeneca relinquishing rights in the US and other territories, except China and South Korea.
The termination of the collaboration agreement and the loss of rights in several territories might be seen as a negative development for AstraZeneca, potentially impacting investor sentiment.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80